Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s129. https://doi.org/10.25251/skin.7.supp.129